Clinical Trial Update: A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines [Phase 3]

View source ↗

Summary

AbbVie completed a Phase 3 study evaluating AGN-151586 injections for treating glabellar lines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Lines

Drugs mentioned

• AGN-151586

Snippet

Sponsor: AbbVie | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED